HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has won U.S. Food and Drug Administration approval for RYBREVANT FASPRO, the ...
The anti-CD40 antibody tegoprubart offers a tacrolimus-free immunosuppression option for preventing islet transplant ...
During a live event, Hannah Choe, MD, analyzed key findings from the AGAVE-201 trial of axatilimab in chronic graft-vs-host disease. A significant number of patients who develop chronic graft-vs-host ...
Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback